Los demás
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DIS-OSTEOSARCOMA |
|---|---|
| Tipo | Enfermedad |
| Aliaces | Osteosarcoma convencionalOSSarcoma osteogénicoОстеосаркома |
| Situación | reviewed 2026-05-19 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-ESMO-BONE-SARCOMA SRC-NCCN-BONE-SARCOMA SRC-NCCN-PEDIATRIC-SARCOMA |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9180/3 |
|---|---|
| icd_o_3_topography | ["C40", "C41"] |
| icd_10 | C40, C41 |
| who_classification | WHO Soft Tissue and Bone Tumours 5th ed (2020): Osteosarcoma — conventional (high-grade intramedullary), telangiectatic, small cell, low-grade central, parosteal, periosteal, high-grade surface, extraskeletal |
Notas
Osteosarcoma is the most common primary malignant bone tumor in children + adolescents. Bimodal age distribution: adolescent growth-spurt peak (10–20y; long-bone metaphyses) and elderly secondary peak (>60y; predominantly Paget disease-associated or post-radiation). Standard-of-care multi-modal treatment (full Indications pending): neoadjuvant chemotherapy → en-bloc surgical resection (limb-salvage preferred; amputation reserved for unresectable / vascular-bundle invasion) → adjuvant chemotherapy. MAP regimen (high-dose methotrexate, doxorubicin, cisplatin) is the global standard from EURAMOS-1 (good-responder arm). Histological necrosis ≥90% at resection predicts favorable outcome; poor responders (<90% necrosis) do NOT benefit from intensification per EURAMOS-1. Genetic relationships drive prevention-workstream surveillance: - Li-Fraumeni (germline TP53): osteosarcoma is the second-most common cancer in this syndrome; Toronto-protocol annual whole-body MRI + bone surveillance recommended. v0.2-B pilot. - Hereditary retinoblastoma (germline RB1) survivors: lifetime osteosarcoma risk markedly elevated, particularly within prior RT field. Long-term surveillance post-retinoblastoma...
Utilizado por
Algoritmos
ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTING- ALGO-CASCADE-LFS-CARRIER-FAMILY-TESTINGALGO-CHOMPRET-2015-LFS- ALGO-CHOMPRET-2015-LFSALGO-STS-ADVANCED-1L- ALGO-STS-ADVANCED-1L
Enfermedad
DIS-CHOROID-PLEXUS-CARCINOMA- Carcinoma de plexo coróideDIS-RETINOBLASTOMA- RetinoblastomaDIS-RHABDOMYOSARCOMA- Rabdomyosarcoma
Indicación
IND-ROTHMUND-THOMSON-CARRIER-INTENSIFIED- IND-ROTHMUND-THOMSON-CARRIER-INTENSIFIEDIND-ROTHMUND-THOMSON-CARRIER-SURVEILLANCE- IND-ROTHMUND-THOMSON-CARRIER-SURVEILLANCE
Señal de alerta
RF-IATROGENIC-PRIOR-RADIATION-PREVENTION- Historia de la exposición a la radiación terapéutica hace ≥5 años a una región del cuerpo...RF-LI-FRAUMENI-CONFIRMED-CARRIER- El paciente tiene una variante patógena confirmada de la gérmena TP53 (prueba de gérmena positiva, distinción...RF-ROTHMUND-THOMSON-CONFIRMED-CARRIER- Variantes patogénicas / patogénicas probables de la línea germinal biallélica confirmadas en RECQL4 (RecQ-like...RF-WERNER-CONFIRMED-CARRIER- Variantes patogénicas / patogénicas probables biallélicas confirmadas en WRN (RECQL2; Wern...